Asthma
Conditions
Brief summary
The QUARTZ study is a retrospective observational cohort study using a prevalent new-user design and U.S. healthcare claims data to evaluate treatment effectiveness among patients with asthma. The study compares the real-world effectiveness of switching from albuterol-only rescue therapy to albuterol/budesonide versus adding low-dose inhaled corticosteroids (ICS) or leukotriene receptor antagonists (LTRA) while continuing albuterol. The primary objective is to assess the comparative effectiveness of these treatment strategies in reducing severe asthma exacerbations in routine clinical practice in the United States.
Interventions
OTHERNone (observational study)
Not applicable since it's an observational study. There are three study cohorts: 1) Airsupra cohort 2)Albuterol and low-dose ICS comparator cohort and 3) Albuterol and LTRA comparator cohort.
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Asthma patients with at least one prescription record (identified by NDC or Healthcare Common Procedure Coding System \[HCPCS\] codes) for Airsupra (Airsupra cohort), LD ICS or LTRA, (comparator cohort) since January 2023. * Patients with at least one prescription record (based on NDC or HCPCS codes) of albuterol within the 12 months prior to the first Airsupra or the controller medications prescription date * Patients aged ≥18 years on the index date * Patients with ≥12 months of continuous insurance enrolment prior and 12 months after index date.
Exclusion criteria
* Patients with at least one medical claim with an ICD-10 code within the 12 months prior to the index date for any of the chronic respiratory conditions or systemic inflammatory diseases routinely treated with systemic corticosteroids (SCS) * Patients with any prescription record for any ICS or other controller therapies (including SAMA, LABA, LAMA, LTRA, theophylline or biologics) within the 12 months prior to the and inclusive of index date (the index therapy defining cohort entry (LD ICS for the LD ICS cohort; LTRA for the LTRA cohort is permitted on the index date) * Patients with maintenance OCS use within the 12 months prior to and inclusive of the index date * Airsupra patients with a concomitant SABA prescription record on the index date
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severe exacerbations during follow-up: annualized asthma exacerbation rates (AAER) by cohort, overall and by setting (IP, ED/urgent care, outpatient); plus absolute rates and rate ratios comparing Airsupra with each comparator cohort | Follow-up starts the day after index and ends at the earliest of death, data end, insurance disenrollment, loss to follow-up, or switch to the alternative rescue treatment, up to 36 months; add-on maintenance therapy does not censor follow-up. | To describe and compare the occurrence of severe exacerbations observed among the Airsupra cohort and each comparator cohort. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first severe exacerbation: KM curves, median time by arm (if estimable), and Cox PH HRs comparing Airsupra with each comparator. Also, the proportion with at least 1 severe exacerbation at 3, 6, 9, and 12 months after treatment initiation. | Follow-up period for each patient starts the day after the index date and ends at the earliest date of death, end of data, end of insurance enrollment, loss to follow up, or switch to the alternative rescue treatment up to 36 months | To describe and compare the time to first severe exacerbation among the Airsupra cohort and each comparator cohort. |
| Cumulative inhaled corticosteroid exposure (beclomethasone equivalent µg/year) | Follow-up period for each patient starts the day after the index date and ends at the earliest date of death, end of data, end of insurance enrollment, loss to follow up, or switch to the alternative rescue treatment up to 36 months | To describe exposure to corticosteroid treatments among the Airsupra cohort and each comparator cohort |
| Cumulative systemic corticosteroid exposure (prednisone equivalent mg/year) | Follow-up period for each patient starts the day after the index date and ends at the earliest date of death, end of data, end of insurance enrollment, loss to follow up, or switch to the alternative rescue treatment up to 36 months | To describe exposure to corticosteroid treatments among the Airsupra cohort and each comparator cohort |
| Total SCS exposure days | Follow-up period for each patient starts the day after the index date and ends at the earliest date of death, end of data, end of insurance enrollment, loss to follow up, or switch to the alternative rescue treatment up to 36 months | To describe exposure to corticosteroid treatments among the Airsupra cohort and each comparator cohort |
| SCS burst rates | Follow-up period for each patient starts the day after the index date and ends at the earliest date of death, end of data, end of insurance enrollment, loss to follow up, or switch to the alternative rescue treatment up to 36 months | To describe exposure to corticosteroid treatments among the Airsupra cohort and each comparator cohort |
Contacts
CONTACTAstraZeneca Clinical Study Information Center
Outcome results
None listed